Eleven Biotherapeutics Announces Executive Change
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- CAE agrees to sell Flightscape unit to SITA for $500 million
Eleven Biotherapeutics (EBIO) CFO Resigns
June 24, 2015 4:01 PM EDTEleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Gregory D. Perry has resigned as Chief Financial and Business Officer, effective July 3, 2015. John J. McCabe, Elevens Vice President of Finance and Business Operations, is promoted to assume the roles of Principal Financial Officer and Principal Accounting Officer, reporting directly to Abbie Celniker, PhD, President and Chief Executive Officer of Eleven... More



